News from vasopharm A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

01 Jul, 2020, 08:00 BST vasopharm Announces Last Patient Last Visit in NOSTRA III Traumatic Brain Injury Clinical Trial

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, is pleased...


29 Jan, 2020, 11:15 GMT vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, is pleased...


15 Mar, 2018, 11:13 GMT Vasopharm GmbH Provides Update on Phase III Traumatic Brain Injury Trial - 50% of Patients Enrolled in Trial Triggers Interim Data Review

Vasopharm GmbH, a privately held biopharmaceutical company, today announced that it has recruited half of the 220 patients in the ongoing, pivotal...


06 Sep, 2016, 10:48 BST vasopharm Announces Enrolment of First Patient in Phase III Traumatic Brain Injury (TBI) Trial

NOSTRA III Trial to Assess Efficacy and Safety of Ronopterin (VAS203) in the Treatment of Moderately to Severely Injured Traumatic Brain Injury...


21 Jan, 2016, 09:22 GMT vasopharm Announces EUR 20 Million Fundraising to Progress Treatment for Traumatic Brain Injury

Phase III registration study of VAS203 to commence in H1 2016 vasopharm GmbH, a privately held biopharmaceutical company focusing on novel...


17 Sep, 2012, 09:15 BST vasopharm's Traumatic Brain Injury Drug Exceeds Expectations in Phase IIa Exploratory Clinical Trial

VAS203 demonstrates potential as safe and effective treatment vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of...